Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline plc : Director/PDMR Shareholding

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 08:11pm CEST

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary Shares") on 2 May 2012:

Mr S M Bicknell

Transfer of 250 Ordinary Shares into an ISA at £14.3225 per share.



The Company and the above mentioned person was advised of this transaction on 3 May 2012.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

3 May 2012


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRDSQXLFBLEFXBBD
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
03/23 GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Detail Findings in Glutam..
03/23 GLAXOSMITHKLINE : Reports Findings in Relapsing-Remitting Multiple Sclerosis (Le..
03/23 GLOBAL NICOTINE GUM CONSUMPTION MARK : Reynolds American, Cambrex Corporation, F..
03/23 GLAXOSMITHKLINE : *socgen cuts glaxosmithkline price target to 1300 pence - 'sel..
03/17 GLAXOSMITHKLINE : *berenberg raises glaxosmithkline price target to 1890 pence -..
03/16 GLAXOSMITHKLINE : Study Findings on Neisseria meningitidis Are Outlined in Repor..
03/16 FINDINGS FROM GLAXOSMITHKLINE PLC IN : ...
03/15 GLAXOSMITHKLINE : Submits US Application To Expand Fluarix Indication
03/15 GLAXOSMITHKLINE : New Glaxo boss set for pounds sterling 8.7m pay deal
03/15 Improved margins and Advair hopes lift drugmaker Hikma
More news
Sector news : Pharmaceuticals - NEC
04:16pDJEU Clears Dow-DuPont Deal With Conditions -- Update
09:25a Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/24 WORD ON WALL STREET : Investors Focused On Mylan's Advair Generic, Not EpiPens
03/24 Is Now Too Soon To Buy Adaptimmune?
03/23 Pharma Development Budgets Grow As Roche Remains A Believer
03/23 Gilead Doesn't Offer A Compelling Risk/Reward
03/21 AstraZeneca's Mistakes Mount
Advertisement
Financials ( GBP)
Sales 2017 30 019 M
EBIT 2017 8 449 M
Net income 2017 4 213 M
Debt 2017 13 885 M
Yield 2017 4,79%
P/E ratio 2017 19,72
P/E ratio 2018 17,33
EV / Sales 2017 3,20x
EV / Sales 2018 3,07x
Capitalization 82 137 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,6  GBP
Spread / Average Target 5,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC6.95%102 400
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results